Download Poster (416.45 KB)

Publication
  • ISPOR-Eu •
  • 11 November, 2026 •
  • •

Prevalence and Incidence of Adults with Severe Hypertriglyceridaemia and High Risk of Acute Pancreatitis (≥880 mg/dL): A Systematic Literature Review and Meta-Analysis

Nana Kragh, Chris D. Poole, Louisa D. Rutherford, Zalmai Hakimi, Jameel Nazir, Carly Rich

Available materials

Poster
Publication
  • ISPOR-Eu •
  • 10 November, 2026 •
  • •

Clinical Value of Olezarsen in Preventing the First Acute Pancreatitis Event in Severe Hypertriglyceridemia: A UK Modelling Study

Nana Kragh, Zalmai Hakimi, Jameel Nazir, Michał Pochopień, Tobiasz Lemański, Wiktoria Miszczyk

Available materials

Poster
Publication
  • ISPOR-Eu •
  • 9 November, 2026 •
  • •

Clinical Under-Recognition of Severe Hypertriglyceridemia Patients in Real World Practice: Insights from ICD Coding and Triglyceride Levels

Chuang Liu, Sara Bruce Wirta, Laura Stradford, Carly Rich, Nana Kragh, Aletta Falk

Available materials

Poster
Publication
  • ASN •
  • 24 October, 2026 •
  • •

Pegcetacoplan for 76 weeks maintained proteinuria reduction and stabilized kidney function in C3G or primary IC-MPGN

Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Fadi Fakhouri

Available materials

Oral Presentation
Publication
  • ASN •
  • 24 October, 2026 •
  • •

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3G or Primary IC-MPGN: PRISM-C3, a Multi-Country Phase 4 Study

David Kavanagh, Matthew C Pickering, Terence Cook, Moglie Le Quintrec, Véronique Frémeaux-Bacchi, Virginia Taliadouros, Elena Surova, Nicholas Webb, Fadi Fakhouri

Available materials

Poster
Publication
  • ASN •
  • 24 October, 2026 •
  • •

Pharmacokinetic (PK), pharmacodynamic (PD) and exposure–response (E–R) analysis of pegcetacoplan in C3 glomerulopathy (C3G) & primary immune-complex membranoproliferative glomerulonephritis (pIC-MPGN)

Ali Keshavarz, Eli Khankin, Joel Melnick, Derek Wachtel, Shiva Kalyan Voruganti

Available materials

Poster
Publication
  • ASN •
  • 23 October, 2026 •
  • •

Pegcetacoplan for 76 weeks maintains proteinuria reduction and eGFR stabilization for pediatric patients: VALIANT+VALE subgroup analysis

Bradley P Dixon, Larry A Greenbaum, Gema Ariceta, Yael Borovitz, Antonio Mastrangelo, Nabil Melhem, Naoya Fujita, Nicole CAJ Van de Kar, Dean Wallace, Eli Khankin, Anwesha Mukherjee, Elena Surova, Johan Szamosi, Marina Vivarelli, Christoph Licht, Carla M Nester

Available materials

Oral Presentation
Sign up for alerts